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ABSTRACT: The mediator complex-associated cyclin de-
pendent kinase CDK8 regulates β-catenin-dependent tran-
scription following activation of WNT signaling. Multiple lines
of evidence suggest CDK8 may act as an oncogene in the
development of colorectal cancer. Here we describe the
successful optimization of an imidazo-thiadiazole series of
CDK8 inhibitors that was identiﬁed in a high-throughput
screening campaign and further progressed by structure-based
design. In several optimization cycles, we improved the
microsomal stability, potency, and kinase selectivity. The
initial imidazo-thiadiazole scaﬀold was replaced by a 3-methyl-
1H-pyrazolo[3,4-b]-pyridine which resulted in compound 25
(MSC2530818) that displayed excellent kinase selectivity,
biochemical and cellular potency, microsomal stability, and is orally bioavailable. Furthermore, we demonstrated modulation of
phospho-STAT1, a pharmacodynamic biomarker of CDK8 activity, and tumor growth inhibition in an APC mutant SW620
human colorectal carcinoma xenograft model after oral administration. Compound 25 demonstrated suitable potency and
selectivity to progress into preclinical in vivo eﬃcacy and safety studies.
■ INTRODUCTION
In contrast to other members of the CDK family (e.g., CDK1,
CDK2, and CDK4/6), neither CDK8 nor its paralogue CDK19
are required for the regulation of cell cycle progression. Instead,
CDK8 and CDK19 together with MED12/12L and MED13/
13L respectively form a regulatory kinase module for the
mediator complex.1,2 The mediator complex is a large protein
assembly that couples gene-speciﬁc transcriptional regulators to
the general RNA polymerase II transcription machinery.2−7
CDK8 and CDK19 participate in the regulation of transcription
through phosphorylation of RNA polymerase II8 and other
transcription factors to regulate their activity or tag them for
proteosomal degradation.9−14
The role of CDK19 in cellular biology and human disease is
not well understood and is the subject of ongoing
investigation.1 However, in contrast, CDK8 is much better
characterized and has been proposed to act as an oncogene in
colon cancer15 and approximately 60% of colorectal cancers
have increased CDK8 gene copy number.16 Moreover, a worse
prognosis in colon, breast, and ovarian cancer is linked to
increased CDK8 expression.17 CDK8 is also essential for cell
proliferation in melanoma.18 Additional cancer-relevant activ-
ities of CDK8 include growth factor-induced transcription,
modulation of TGF β-signaling,13 and phosphorylation of the
Notch intracellular domain.19,20 Although knockout of CDK8
prevents embryonic development due to its essential role in the
pluripotent stem cell, other studies have reported that CDK8
depletion does not aﬀect the growth of normal cells.15,21,22
CDK8 may also contribute to tumorigenesis through
activation of β-catenin regulated gene expression,16 a core
transcriptional regulator of canonical WNT signaling. Con-
sistent with this observation, expression of the CDK8 gene is
correlated with activation of β-catenin in colon and gastric
cancers.17,23 Because of its involvement as a regulator of WNT/
β-catenin signaling, CDK8 may be linked with disorders and
diseases in which activation of WNT/β-catenin is crucial such
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as hyperproliferative, inﬂammatory, or degenerative disorders
and several malignant diseases.19,20
An extensive contemporary review reports the current status
of small-molecule inhibitors for CDK8/CDK19 and highlights
an increasing interest in targeting CDK8;24 in addition, a recent
report demonstrates a potential use for CDK8 inhibitors in
AML.25 We recently described the discovery of small-molecule
inhibitors of CDK8 from a cell-based high-throughput screen
(HTS) seeking WNT signaling inhibitors and also reported
additional diﬀerentiated series of CDK8 inhibitors from a
scaﬀold-hopping approach using the biochemical screen
reported herein.26−30 Here we describe the identiﬁcation of a
novel CDK8/19 chemotype from a biochemical HTS versus
CDK8 and its subsequent optimization, enabled by structure-
based design, to give compound 25, a potent, selective, and
orally bioavailable CDK8/19 ligand suitable for further
progression into preclinical studies.
■ RESULTS AND DISCUSSION
In a CDK8 high-throughput screen using a FRET-based
Lanthascreen binding competition assay,27 we identiﬁed several
hit compounds with submicromolar activity. Our hit series
contained an imidazo[5,1-b][1,3,4]thiadiazole scaﬀold, hence-
forth described as the “imidazo-thiadiazole” series. Initial hits
bore either a 2-substituted benzyl substituent (1 and 2) or a 2-
phenylpyrrolidine ring (3 and 4) attached to the imidazo-
thiadiazole scaﬀold via an amide bond at the 2-position (Table
1). As a cellular readout of WNT signaling, we used our
previously described 7dF3 WNT-speciﬁc reporter gene assay31
and observed a 3−13-fold drop oﬀ from in vitro CDK8 binding
aﬃnity to cell-based activity for compounds 1−4.
Introduction of a methyl group to the alkyl linker resulted in
a 6-fold drop in biochemical potency (compound 2, Table 1),
and the pyrrolidine moiety was favored over an alkyl chain
linker by virtue of signiﬁcantly increased cell-based potency and
improved metabolic stability (compounds 3 and 4). Hydrogen
to ﬂuorine exchange at the para position of the phenyl ring
(compounds 3 to 4) did not inﬂuence biochemical or cell-based
potency; however, we noted a slight improvement in
microsomal stability (Table 1). To further explore the impact
of the para-substitution and stereochemistry at the pyrrolidine
2-position, the racemic form and both of the enantiomers
bearing a p-Cl-phenyl were synthesized (Table 2). The racemic
form (5) showed modest biochemical and cell-based activity.
Interestingly, the S-enantiomer (6) was signiﬁcantly more
active than the R-enantiomer (7); however, the microsomal
stability of both enantiomers was in the same range.
To understand the binding mode and to inform further
medicinal chemistry design, we determined the crystal structure
of the most potent enantiomer (6) bound to CDK8/cyclin C
(Figure 1A). Compound 6 is bound to the hinge region of
CDK8 (Ala100) via the nitrogen atom at the 6-position of the
“imidazo-thiadiazole” scaﬀold, while the 5-methyl group points
away from the gatekeeper residue (Phe97) toward the solvent-
exposed channel. The carbonyl group of the C2-amide forms a
cation−π interaction to the catalytic lysine residue (Lys52), too
distant (3.6 Å) to be considered as a hydrogen bond. The sulfur
atom of the “imidazo-thiadiazole” scaﬀold is positioned to form
favorable van der Waals (vdW) interactions to the gatekeeper
residue Phe97. The pyrrolidine ring also forms favorable vdW
interactions to Tyr32 and the side chain of Asp173.
Furthermore, the orientation of the pyrrolidine deﬁnes the
exit vector for the p-Cl-phenyl substituent which itself forms
vdW interactions with Val27, Tyr32, Val35, Leu158, and
Arg356. We did not observe suﬃcient evidence to support a
halogen bond between the chlorine atom and the backbone
CO of Val27: the distance is 2.9 Å, and the angle between
the chlorine atom and the CO functionality of Val27 is
104.7°.
Comparison of the structure of 6 in CDK8/cyclin C with our
recently published crystal structure of a 3,4,5-trisubstituted-2-
aminopyridine chemotype27 (compound 8, CCT251921)
revealed few structural diﬀerences in the active site. The
CDK8 residues in the ATP binding site with the largest
variance between the two crystal structures are shown (Figure
1B). Despite the diﬀerent modes of ligand-binding, the protein
structure is largely conserved. Compounds 6 and 827 both form
H-bond acceptor interactions with the backbone NH of hinge
residue Ala100 and interact with the catalytic lysine (Lys52)
through the amide and lactam carbonyl groups, respectively.
However, interaction with the gatekeeper residue Phe97 is
mediated by the sulfur atom of the thiadiazole scaﬀold 6 as
opposed to the 3-chloro substituent in compound 8. Most
notably, the para-chlorophenyl and N-methylindazole rings that
project into a similar region in the CDK8 solvent channel are
linked to the hinge-binding scaﬀold through diﬀerent
architectures in the two series (Figure 1B).
We were concerned that the thiadiazole ring may be prone to
oxidative metabolism and therefore set out to discover a
modiﬁed scaﬀold hop in order to mitigate this risk. In addition,
we wished to explore variation of the pyrrolidine ring and its
Table 1. HTS Hits from the “Imidazo-thiadiazole” Series
Table 2. Determination of Optimal Pyrrolidine
Stereochemistry
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pendant 2-phenyl substituent in order to optimize potency and
metabolic stability.
1. Scaﬀold Hop from the Hinge Binding Motif of the
“Imidazo-thiadiazole” Series. We modiﬁed the “imidazo-
thiadiazole” scaﬀold based upon the crystal structure of
compound 6 in CDK8/cyclin C (Figure 1A) according to
SZMAP32 and WaterMap33 analysis (see Figure 2). We ran
these calculations for the ligand-deleted form of the crystal
structure of compound 6 with CDK8/cyclin C. Given this
calculation setup, we could analyze the energy of predicted
water sites inside the hinge binding region and identify possible
handles for scaﬀold variations.
Solvent ZAP Mapping (SZMAP; ZAP is a Poisson−
Boltzmann solver) represents a mixture of an implicit and
explicit solvent model. In brief, a grid with a spacing of 0.25 Å is
generated inside the protein active site and an explicit water
molecule is positioned at each grid point with multiple
orientations, followed by an implicit solvent Poisson−
Boltzmann calculation.34,35 These calculations can be done
with and without the ligand. For our analysis, we performed the
calculations without the ligand. Once the calculations are
completed for all grid points, an overall energy grid for the
presence or absence of water molecules is computed. The
predicted water molecules show diﬀerent characteristics based
on their energy values: a water molecule is characterized as
“hydrophobic” if its energy value is positive, otherwise it is
characterized as “hydrophilic”.
The WaterMap methodology is a combination of MD
simulation36 with the inhomogeneous ﬂuid approach.37 In brief,
this approach calculates the enthalpic and entropic contribu-
tions of binding per predicted water molecule. Consistent with
the SZMAP analysis, the ligand was left out for the WaterMap
calculations. If the overall free energy per predicted water
molecule is positive, it is speciﬁed as “unhappy water”, whereas
a predicted negative free energy indicates a “happy water”.
The interpretation of SZMAP and WaterMap calculations
can be used for the diﬀerentiation of binding modes observed
for highly structurally related ligands38 and for rationalization of
SAR,33,39 kinase selectivity,40 and binding kinetics.41 In the
course of our studies, we employed SZMAP and WaterMap for
the interpretation of modiﬁcations to the hinge binding
scaﬀold. By applying these computational approaches, we
explored changes to the ﬁve-membered ring of the hinge
binding motif and selected a range of 5,6-bicyclic scaﬀolds for
synthesis. The remainder of the molecule was ﬁxed by the S-p-
Cl-2-phenyl-pyrrolidine motif (Table 3) and compounds were
scored by WaterMap, see Figure 2C.
Analysis of the predicted water sites via SZMAP (see Figure
2B) revealed that hydrophilic water molecules are favored
directly adjacent to the hinge residues Ala100 and Asp98. This
is consistent with the corresponding hydrophilic hinge-binding
motifs of our selected scaﬀold replacements. The remaining
part of the hinge-binding region is predicted to be mostly ﬁlled
with hydrophobic water molecules. Such water molecules can
be replaced by both hydrophobic and hydrophilic moi-
eties.42−44 On the basis of this ﬁnding, we ranked our
compound ideas by WaterMap scores. In addition, the
characterization of predicted water sites by SZMAP calculations
revealed that broad scaﬀold variations should be possible. The
new compound design ideas were also prioritized based upon
their synthetic tractability and potential for improved micro-
somal stability. Figure 2B (lower panel) depicts the
contribution from each ligand atom resulting from water
molecule replacement at the same position. This analysis
underscores the 30-fold diﬀerence in CDK8 aﬃnity between
compounds 9 and 10: the favorable binding contribution by
addition of a methyl group at the 5-position is driven by the
replacement of an “unhappy” water molecule; this ﬁnding is
consistent with both the WaterMap and SZMAP predictions.
We performed a ranking of our compounds based on the
WaterMap scores for the docking solutions of compounds from
Tables 1 and 2 which adopt a similar hinge-binding mode. On
the basis of an acceptable trend between WaterMap scores and
pIC50, we also scored new compound ideas from Table 3. The
outcome of this ranking is given in Figure 2C (lower panel),
suggesting a weak correlation between the WaterMap-based
analysis and the in vitro potency of compounds from Table 3.
We omitted compound 11 from this analysis because we
anticipate a diﬀerent binding mode; indeed, a 2850-fold
decrease in potency was seen with the introduction of an sp2
Figure 1. (A) Crystal structure of CDK8/cyclin C complexed with compound 6 (blue). Hydrogen bonds are displayed as dashed lines. The cation−
dipole interaction between the carbonyl atom and the catalytic Lys52 is also shown. The key amino acids are given in stick representation. (B)
Alignment of the CDK8/cyclin C structures of compound 6 (ligand: blue/protein: salmon) and compound 8 (ligand magenta/protein: green). The
residues which deviate most between the two structures are highlighted in stick mode: Lys52, and Asp173. Tyr-32 removed for clarity.
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Figure 2. (A) SZMAP and WaterMap calculations have been performed for the crystal structure of compound 6 complexed to CDK8/cyclin C. For
clarity, only part of the ligand denoted in bold (A) is shown in B and C. (B) Upper panel: Only the hinge region is shown. SZMAP analysis of the
CDK8/compound 6 crystal structure: yellow spheres correspond to water sites bearing hydrophilic character and pink spheres correspond to water
sites bearing hydrophobic character. Lower panel: The contribution from each ligand atom resulting from water molecule replacement at the same
position is shown. The character of the ligand-displaced water spheres are depicted as mesh: yellow mesh corresponds to hydrophilic water spheres
and green mesh corresponds to hydrophobic water spheres. The size of the water spheres correspond to the relative energy gain obtained by
replacement of the particular water sphere by each ligand atom. (C) Upper panel: Only the hinge region is shown for clarity; the full ligand is
depicted in (A). WaterMap analysis of the CDK8/compound 6 crystal structure: red spheres correspond to “unhappy” water molecules and yellow
spheres to “happy” water molecules. Lower panel: WaterMap scoring versus CDK8 pIC50 for the compounds from Tables 1 and 2 (blue dots) and
the compounds from Table 3 (red dots), r2 = 0.54.
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nitrogen atom juxtaposed to the CO backbone group of
Asp98, see compound 11, versus the corresponding hydrogen
bond donor in compound 10 (Table 3). However, compound
11 showed good microsomal stability, indicating that an
appropriate scaﬀold hop could signiﬁcantly improve stability
to oxidative metabolism. Pleasingly, the introduction of a
methyl group at the 3-position of the indazole 9 to give 10
resulted in a 22-fold improvement in biochemical potency and a
166-fold increase in cell-based potency; however, no improve-
ment in microsomal stability was observed consistent with the
increased lipophilicity of compound 10 versus 9.
In summary, the potency increase arising from introduction
of the C3-methyl group in compound 10 is consistent with our
SZMAP analysis (Figure 2B). However, we recognized that the
indazole C3-methyl group could be susceptible to oxidative
metabolism and therefore introduced a more polar amino
group at this position (compound 13), cognizant that improved
hinge-binding interaction with the backbone carbonyl of Ala100
may also be realized (Figure 1). This tactic maintained in vitro
CDK8 potency and improved microsomal stability as desired
but unfortunately led to a 47-fold drop in cellular potency
(compared to compound 10) despite good Caco2 ﬂux (PappA‑B
= 33.7 × 10−6 cm s−1) and low eﬄux ratio (2.2).
Compound 13 proved optimal in terms of biochemical
potency and metabolic stability and was further proﬁled in a
broad kinase panel to discover any kinase selectivity issues
(Supporting Information, Table S2). Five oﬀ-target kinases
were detected (JAK1, JAK2, JAK3, ROCK-II, and TYK2) and
were subject to IC50 determination to conﬁrm potency (Table
4). Consequently, we aimed to improve selectivity versus these
oﬀ-target kinases in subsequent medicinal chemistry optimiza-
tion.
2. Variation of the Ring Linker Size and Halogen
Substituents. To inform our medicinal chemistry design, we
calculated selectivity grids45 for the CDK8/compound 6 crystal
structure, see Figure 3A, and selectivity grids for the most
notable oﬀ-target kinases, see Figure 3B. Selectivity grids
represent a plausible interpretation of regions within binding
pockets which may be targeted to improve (or to lose)
selectivity.45 These selectivity grids suggested that the para-
halogen substituent of the phenyl ring and the 3-amino group
of the indazole scaﬀold represented possible variation points to
achieve selectivity for CDK8 over the oﬀ-target kinases, see
Figure 3A. Furthermore, this analysis suggested that sub-
stitution at the solvent-exposed region of the binding pocket
would nonspeciﬁcally increase potency against the oﬀ-target
kinases, see Figure 3B. Therefore, we decided to vary the para-
halogen substituent as well as the pyrrolidine ring and also to
methylate the 3-amino group on the indazole scaﬀold in order
to improve the selectivity and cell-based activity of compound
13 (Tables 3 and 5).
The kinase selectivity data conﬁrmed the hypothesis that the
para-substituent could act as selectivity handle: The %
inhibition values, which refer to single point measurements of
percent inhibition at 1 μM, demonstrate that the oﬀ-target
activity versus the JAK family decreases as the para-halogen
substituent is varied from Br to Cl to F. Selectivity could be
further improved by modiﬁcations of the ring linker size or
switching from a 1,2-substitution pattern to a 1,3-substitution
pattern of the pyrrolidine linker. Pleasingly, the aﬃnity for oﬀ-
target kinases was also reduced by methylating the 3-amino
group.
In summary, variation of the halogen substituent in the para-
position of the phenyl ring showed a clear trend: while the on-
target biochemical CDK8 and cellular 7dF3 potencies
decreased from Br to Cl to F in the matched trio 14, 13, and
15, less potent oﬀ-target activity versus the JAK family, ROCK-
II and TYK2, was also observed. Interestingly, all three
compounds were metabolically stable. Replacement of
pyrrolidine (15) with azetidine (16) retained biochemical
potency and microsomal stability with slight loss in cell-based
potency. The same held true when increasing the ring size from
a pyrrolidine to a piperidine linker (17) although cell-based
potency was further eroded. Alteration of the substitution
pattern at the pyrrolidine from 1,2 to 1,3 showed a moderate
loss of biochemical and cellular potency (compare 18 with 13)
while maintaining good microsomal stability. Finally, the
addition of a methyl group to the 3-amino functionality of
the indazole scaﬀold resulted in equipotent biochemical and
cellular activity (compare 19 with 13) combined with a slight
loss of microsomal stability.
We next determined the crystal structure of compound 17
bound to CDK8/cyclin C (Figure 4A) and examined the
superposition of 17 with compound 6 (Figure 4B). The
indazole hinge-binding motif is located at the same position as
the “imidazo-thiadiazole” scaﬀold of 6. N1 of the indazole
scaﬀold forms an additional hydrogen bond to the CO
backbone of Asp98. The carbonyl moiety linking the para-halo-
phenyl piperidine to the hinge-binding scaﬀold is located at the
Table 3. Variation of the Hinge Binding Motif of the
“Imidazo-thiadiazole” HTS Scaﬀold
Table 4. Kinase Proﬁle Data for 13 (See Also Supporting
Information, Table 2), Sorted Alphabetically
kinase IC50 (nM) % inhibition at 1 μM
CDK8 4.9 100
JAK1 90 86
JAK2 286 84
JAK3 219 79
ROCK-II 1330 42
TYK2 279 70
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.6b00597
J. Med. Chem. 2016, 59, 9337−9349
9341
same position in both ligands. Interestingly, the exocyclic amino
group in the 3-position of the indazole does not form a
hydrogen bond with the backbone carbonyl atom of Ala100
(the heavy atom distance = 3.4 Å) and the electron density
surrounding this amino group is not consistent with the
placement of a water molecule. These observations are
Figure 3. (A) Selectivity grids for the CDK8-speciﬁc regions of the active site. In general, regions around the para-substituted halogen in the phenyl
ring as well as the region adjacent to the pyrrolidine ring can be considered as potential selectivity handles. (B) Selectivity grids of the ATP binding
pocket which have the potential to drive increased potency for oﬀ-target kinases such as the JAK family.
Table 5. Variations of the Ring Linker Size and para-Substitution of the Phenyl Ring
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consistent with SZMAP and WaterMap calculations that did
not predict an energetically favorable water molecule in this
region. Compound 6 was 12-fold more potent than 17 versus
CDK8, and we reasoned that this diﬀerence may be driven by
the halogen substituent; indeed, comparison of the matched
molecular pair 15 and 17, which only diﬀer by the ring linker
size (pyrrolidine vs piperidine), were equipotent (32 vs 45
nM). Although the ring size is increased from a ﬁve-membered
pyrrolidine linker to a six-membered piperidine linker, the p-F
phenyl ring is placed at an almost identical position compared
to compound 6, see Figure 4B. Comparing the ﬂuorine atom
(compound 17) to the chlorine atom (compound 6), the
halogen to Val27 carbonyl distance is increased from 2.9 Å
(compound 6, chlorine) to 3.7 Å (compound 17, ﬂuorine). We
observed only one other structural diﬀerence: the distance
between the carbonyl linker and the catalytic lysine Lys52 (3.6
Å for compound 6 and 4.6 Å for compound 17). Thus, we
attribute the increased potency of compound 6 to the improved
interaction of the para-Cl atom with Val27 compared to the
para-F atom in compound 17 together with improved
interaction between the carbonyl linker and Lys52 for
compound 6.
Although we had improved the kinase selectivity and
maintained microsomal stability by variations of the pyrrolidine
linker and para-halogen substituent, the resultant compounds
(16 and 17) lacked the desired biochemical potency and
cellular activity. Comparison of the matched molecular pair C3-
amino with C3-methyl (13 vs 10) indicated that the C3-methyl
substitution resulted in good cellular potency, albeit with
poorer microsomal stability. Consequently, we selected the C3-
methylindazole scaﬀold for further progression.
3. Optimization of Microsomal Stability. In vitro
metabolite identiﬁcation studies indicated that the pyrrolidine
ring linker is the major site of oxidative metabolism for
compound 10. Thus, we prepared close analogues of
compound 10 with reduced overall lipophilicity with the aim
of improving metabolic stability (Table 6).
Replacement of the pyrrolidine by an azetidine (compound
20) did not lead to improved metabolic stability in all species;
however, the racemic piperazine and morpholine derivatives
(21 and 22, respectively) resulted in improved CLint proﬁles
across all species. Disappointingly, we observed a decrease in
the biochemical CDK8 aﬃnity and the cellular potency (Table
6).
In summary, the microsomal stability could be improved by
reducing overall lipophilicity; however, a corresponding drop in
biochemical and cell-based activity was also observed. There-
fore, we attempted to improve the metabolic stability by
reducing the lipophilicity of the molecule through the
introduction of polarity into the hinge-binding scaﬀold.
4. Fine-Tuning of the Hinge Binding Motif. The
pyrazole hinge binding motif was ﬁxed and the six-membered
ring of the indazole scaﬀold was varied by introduction of single
nitrogen atoms in the 4-, 6-, and 7-positions to reduce the
overall lipophilicity of the scaﬀold (compounds 23−25, Table
Figure 4. (A) Crystal structure of 17 (orange) in complex CDK8/cyclin C. The hydrogen bonds are indicated by black dotted lines. (B)
Superposition of crystal structures of compounds 17 (orange) and 6 (blue).
Table 6. Variations of the Ring Linker Size Based on the 3-
Methyl-indazole Scaﬀold
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7). Introduction of a nitrogen atom at the 6-position of the
indazole ring (23) resulted in a signiﬁcant drop in biochemical
and cell-based potency. Nitrogen at the 4-position of the
indazole ring gave the most potent analogue (24); however,
this compound showed only modest microsomal stability.
Pleasingly, introduction of a nitrogen atom at the 7-position
(25) resulted in acceptable biochemical CDK8 aﬃnity and
furthermore showed improved microsomal stability (Table 7).
The matched molecular pair compound 25 versus compound
6, where only the hinge binding scaﬀold (“pyrazolo-pyridine” vs
“imidazo-thiadiazole”) has been changed, showed equivalent
biochemical CDK8 aﬃnity and a 11-fold improvement in cell-
based potency together with a signiﬁcant improvement in
mouse and rat microsomal stability.
We next determined the crystal structure of 25 bound to
CDK8/cyclin C (Figure 5A). The carbonyl atom at C5 of the
azaindazole scaﬀold of 25 forms a hydrogen bond to Lys52 and
the side chain of Lys52 moves toward the ligand in comparison
to the binding mode of compound 6 in CDK8/cyclin C (Figure
5B). Overall, the orientation of the active site residues is well
conserved between the crystal structures of 25 and 6. The
interaction pattern is identical except for an additional favorable
interaction from the N1-indazole hydrogen bond donor to the
backbone CO atom of Asp98 for 25. Notably, the additional
nitrogen atom at the 7-position of the indazole scaﬀold does
not elicit any additional favorable interactions consistent with
the corresponding biochemical potencies: indazole 10 (CDK8
IC50 = 1.4 nM) versus aza-indazole 25 (CDK8 IC50 = 2.6 nM).
In a commercially available reporter displacement assay,46
compound 25 binds to CDK8 and CDK19 with similar aﬃnity
(4 nM), as we have previously observed across multiple
chemotypes,27−30 with residence times of 18 and 32 min,
respectively. Potent inhibition of phospho-STAT1SER727, an
established biomarker of CDK8 activity,29 in SW620 human
colorectal carcinoma cells was also observed (pSTAT1SER727
IC50 = 8 ± 2 nM). Furthermore, compound 25 demonstrated
potent inhibition of WNT-dependent transcription in human
cancer cell lines that have constitutively activated WNT
signaling. For example, 25 inhibited the reporter-based
luciferase readout in several cell lines bearing activating
WNT-pathway mutations; LS174T (β-catenin mutant, IC50 =
32 ± 7 nM), COLO205 (APC mutant, IC50 = 9 ± 1 nM) and
demonstrated inhibition of WNT3a ligand-dependent reporter
readout in PA-1 cells (IC50 = 52 ± 30 nM). Compound 25
demonstrated minimal activity in the CEREP panel, being
active on the dopamine transporter (IC50 = 8.5 μM) as the only
activity below 10 μM, and demonstrated minimal hERG
inhibition (18%@10 μM). Testing against a 264 kinase panel
gave inhibition of only a single kinase by more than 50% at 1
μM (GSK3α IC50 = 691 nM). Furthermore, compound 25 is a
soluble CDK8 inhibitor (kinetic solubility >200 μM;
thermodynamic solubilities: 0.399 mg/mL (PBS, pH 7.4),
0.628 mg/mL (FaSSIF, pH 6.5), and 0.836 mg/mL (FeSSIF,
pH 5.0)) with high permeability (PappA−B = 44 × 10
−6 cms−1)
and low eﬄux ratio in Caco-2 cells (ER = 1.5) and does not
inhibit any cytochrome P450 subtypes (Cyp IC50s > 20 μM). In
light of its promising in vitro proﬁle, 25 was further proﬁled in
in vivo pharmacokinetic and pharmacological studies. Overall,
Table 7. Fine-Tuning of the Hinge Binding Motif
Figure 5. (A) Crystal structure of 25 (violet) complexed with CDK8-cyclin C. (B) Superposition of the 25 (violet) and 6 (blue) crystal structures.
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the compound showed acceptable pharmacokinetics (PK) in all
tested preclinical species (Table 8). Prediction of the human
PK was performed by three species allometric scaling corrected
for protein binding and considering interspecies diﬀerences in
intrinsic clearance in liver microsomes. The human clearance
(CL) and volume of distribution at steady-state (Vdss) were
estimated to be low (∼0.14 L/h/kg) and small (0.48 L/kg),
respectively, resulting in a short predicted terminal half-life (2.4
h). Physiologically based pharmacokinetics (PBPK) simulations
suggested that human oral bioavailability may be ≥75% up to
dose level of 500 mg daily.
Compound 25 was then assessed in vivo in an established
SW620 human colorectal cancer xenograft model in female
NCr athymic mice. Tumor-bearing mice were treated orally
with compound 25 (50 mg/kg bid or 100 mg/kg qd) for 16
days. Both schedules gave a similar reduction in tumor growth
(Figure 6A) with T/C ratios (based on ﬁnal tumor weights) of
49% and 57%, respectively. The compound was generally well
tolerated, with no eﬀects on mouse body weight in the qd
administration schedule and manageable body weight loss with
the bid schedule (Figure 6B). We monitored inhibition of
STAT1SER727 phosphorylation by a Luminex immunoassay;
phospho-STAT1SER727 levels were reduced to the limits of
detection 2 h after dosing in both administration schedules and
remained below the control levels even after 24 h, having more
pronounced eﬀects in the bid compared with the qd schedule
(Figure 6C).
■ CONCLUSIONS
In an HTS campaign using a FRET-based Lanthascreen
binding competition assay, we identiﬁed a chemical series
comprising an imidazo-thiadiazole scaﬀold with exemplar
compounds demonstrating IC50 values in the 60−780 nM
range (Table 1); however, this series lacked suﬃcient
microsomal stability. Determination of the crystal structure of
compound 6 in CDK8/cyclin C demonstrated clear diﬀerences
in binding mode compared to our previously reported 3,4,5
trisubstituted-2-aminopyridine series.27 SZMAP and WaterMap
calculations were applied to identify potential scaﬀold replace-
ments to enhance potency and improve metabolic stability. By
applying these computational approaches, we explored changes
to the skeleton of the ﬁve-membered ring of the imidazo-
thiadiazole hinge binding motif and discovered a series of
indazole-based scaﬀold replacements. Notably, 3-methyl
indazole 10 demonstrated potent biochemical and cell-based
potency; however, insuﬃcient metabolic stability precluded
further progression. Replacement of the C3-methyl substituent
with a C3-amino group gave compound 13, which demon-
Table 8. Pharmacokinetic Proﬁle of Compound 25
species
f u
(%)
Vdss
(L/kg)
plasma Cl
(L/h/kg) %Qh t1/2 (h) F
mouse 13 0.59 1.37 22.5 0.45 0.25
rat 19 1.62 1.50 34.6 0.86 0.66
dog 50 1.47 1.35 53.8 0.83 0.39
human
prediction
16 ∼0.48 ∼0.14 12.1 ∼2.4 >0.75a
aPredicted by PBPK modeling (GastroPlus).
Figure 6. Eﬃcacy study of compound 25 in SW620 human colorectal cancer xenografts. (A) Tumor growth rates expressed as volumes (mean ±
SEM). (B) Mouse body weights expressed as % of day 0 values. (C) Phospho-STAT1SER727 levels relative to total STAT1 levels and expressed as %
vehicle controls at each time point. (D) Free plasma concentrations of compound 25 over time at the two dose schedules (50 mg/kg bid or 100 mg/
kg qd).
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strated optimal biochemical potency and metabolic stability but
suﬀered from undesirable oﬀ-target kinase aﬃnity.
We employed selectivity grids to rationalize key regions for
the modulation of kinase selectivity for the most notable oﬀ-
target kinases, and discovered that selectivity could be
improved by modiﬁcations to the pyrrolidine ring and by
variation of the para-halogen substituent on the pendant phenyl
ring to give, for example, the selective and metabolically stable
para-ﬂuorophenylpiperidine analogue 17. Crystallization of 17
in CDK8/cyclin C revealed a conserved binding mode;
however, 17 lacked the desired biochemical potency and
cellular activity.
Revisiting the C3-methylindazole series and applying the
principle of reduced lipophilicity to abrogate oxidative
metabolism enabled the synthesis of potent and selective
analogues with improved cell-based potency compared to 3-
amino-indazole 17. In particular, the 7-azaindole scaﬀold
exempliﬁed by compound 25, which demonstrated an optimal
compromise of biochemical and cell-based potency coupled
with acceptable in vitro metabolic stability that resulted in a
favorable in vivo oral pharmacokinetic proﬁle in mouse, rat, and
dog. Compound 25 demonstrated reduction of tumor growth
rates of established human SW620 colorectal carcinoma
xenografts using two diﬀerent oral dosing schedules. We
observed concomitant inhibition of a target engagement
biomarker phospho-STAT1SER727 consistent with pharmacoki-
netic exposure.
In light of its potent and selective proﬁle coupled with good
oral pharmacokinetics and duration of in vivo target engage-
ment on oral dosing, compound 25 (MSC2530818) was
selected for progression into further preclinical in vivo animal
eﬃcacy and safety studies.
■ EXPERIMENTAL SECTION
Chemistry. Commercially available starting materials, reagents, and
dry solvents were used as supplied. Column chromatography was
performed on a CombiFlash Companion puriﬁcation system using
Teledyne Isco silica cartridges. Preparative TLC was performed on
Merck plates. Preparative HPLC was conducted according the
following methods. Method A: injections of the sample were made
onto a SunFire C18 OBD column (100 Å, 5 μm, 30 mm × 100 mm).
Chromatographic separation at room temperature was carried out
using Agilent Technologies, 1260 Inﬁnity, acetonitrile:water gradient
(both modiﬁed with 0.1% triﬂuoroacetic acid) at a ﬂow rate of 50 mL/
min. Chiral preparative HPLC was conducted according the following
methods. Method B: Injections of the sample were made onto a
ChiralPak AD-H column (5 μm, 4.6 mm × 250 mm). Chiral
chromatographic separation was carried at room temperature out using
SFC Berger Minigram, CO2/methanol (85:15) + 0.5% diethyl amine
at a ﬂow rate of 5 mL/min. Method C: Injections of the sample were
made onto a ChiralPak AS-H column (5 μm, 4.6 mm × 250 mm).
Chiral chromatographic separation was carried at room temperature
out using SFC Berger Minigram, CO2/methanol (60:40), modiﬁed
with 0.5% diethyl amine, at a ﬂow rate of 5 mL/min. Method D:
Injections of the sample were made onto a ChiralPak AD-H column (5
μm, 4.6 mm × 250 mm). Chiral chromatographic separation was
carried at room temperature out using SFC Berger Minigram, CO2/
methanol (75:25) + 0.5% diethyl amine, at a ﬂow rate of 5 mL/min.
Additional methods are directly described in the procedures. 1H NMR
spectra were recorded on a Bruker Avance-500, Avance 400, Avance II
400, or Avance 300. Samples were prepared as solutions in a
deuterated solvent and referenced to the appropriate internal
nondeuterated solvent peak. 13C NMR spectra were recorded at 101
MHz using an internal deuterium lock. The following internal
references were used: CDCl3, CD3OD, and DMSO-d6. LC/MS and
HRMS analysis was performed on an Agilent 1200 series HPLC and
diode array detector coupled to a 6210 time-of-ﬂight mass
spectrometer with dual multimode APCI/ESI source. Analytical
separation was carried out according to the following method. Method
E: Analytical separation was carried out on a Chromolith Speed ROD
column (RP-18e, 50 mm × 4.6 mm) using a ﬂow rate of 2.4 mL/min
in a 3.9 min gradient elution with detection at 220 nm. The mobile
phase was a mixture of water containing 0.05% formic acid (solvent A)
and acetonitrile containing 0.04% formic acid (solvent B). Gradient
elution was as follows: 95:5 (A/B) to 0:100 (A/B) over 2.8 min, 0:100
(A/B) for 0.5 min, and then reversion back to 95:5 (A/B) over 0.1
min, ﬁnally 95:5 (A/B) for 0.5 min. LC/MS and HRMS analysis was
also performed on a SHIMADZU LC-MS machine consisting of an
UFLC 20-AD system with a LC-20 AD pump, SPD-M20A UV
detector, and a LCMS 2020 MS detector. Method F: analytical
separation was carried out on a Shim-pack XR-ODS column (2.2 μM,
3.0 mm × 50 mm) using a ﬂow rate of 1.0 mL/min in a 3.6 min
gradient elution with detection at 220 nm. The mobile phase was a
mixture of water (solvent A) and acetonitrile (solvent B), both
containing 0.05% TFA. Gradient elution was as follows: 95:5 (A/B)
over 0.01 min, then 95:5 to 0:100 (A/B) over 2.2 min, 0:100 (A/B)
for 1.0 min, and then reversion back to 99:5 (A/B) over 0.1 min.
Method G: analytical separation was carried out on a Shim-pack VP-
ODS column (2.2 μM, 3.0 mm × 50 mm) using a ﬂow rate of 1.0 mL/
min in a 5.6 min gradient elution with detection at 220 nm. The
mobile phase was a mixture of water (solvent A) and acetonitrile
(solvent B), both containing 0.05% TFA. Gradient elution was as
follows: 95:5 (A/B) over 0.01 min, then 95:5 to 0:100 (A/B) over 4.2
min, 0:100 (A/B) for 1.0 min, and then reversion back to 99:5 (A/B)
over 0.1 min. Method H: LC/MS and HRMS analysis was performed
on a Waters Acquity UPLC and diode array detector coupled to a
Waters G2 QToF mass spectrometer ﬁtted with a multimode ESI/
APCI source. Analytical separation was carried out at 30 °C on a
Phenomenex Kinetex XB-C18 column (30 mm × 2.1 mm, 1.7u, 100A)
using a ﬂow rate of 0.5 mL/min in a 2 min gradient elution with
detection at 254 nm. The mobile phase was a mixture of methanol
(solvent A) and water (solvent B), both containing formic acid at
0.1%. Gradient elution was as follows: 10:90 (A/B) to 90:10 (A/B)
over 1.25 min, 90:10 (A/B) for 0.5 min, and then reversion back to
10:90 (A/B) over 0.15 min, ﬁnally 10:90 (A/B) for 0.1 min. Method I:
LC/MS and HRMS analysis was performed on an Agilent 1200 series
HPLC and diode array detector coupled to a 6210 time-of-ﬂight mass
spectrometer with dual multimode APCI/ESI source. Analytical
separation was carried out at 30 °C on a Merck Purospher STAR
column (RP-18e, 30 mm × 4 mm) using a ﬂow rate of 1.5 mL/min in
a 4 min gradient elution with detection at 254 nm. The mobile phase
was a mixture of methanol (solvent A) and water (solvent B), both
containing formic acid at 0.1%. Gradient elution was as follows: 10:90
(A/B) to 90:10 (A/B) over 2.5 min, 90:10 (A/B) for 1 min, and then
reversion back to 10:90 (A/B) over 0.3 min, ﬁnally 10:90 (A/B) for
0.2 min. The following references masses were used for HRMS
analysis: caﬀeine [M + H]+ 195.087652; (hexakis(1H,1H,3H-
tetraﬂuoropentoxy)phosphazene [M + H]+ 922.009798) and hexakis-
(2,2-diﬂuoroethoxy)phosphazene [M + H]+ 622.02896 or reserpine
[M + H]+ 609.280657. All compounds submitted for biological testing
were determined to be >95% pure by methods E, F, or G unless stated
otherwise.
The synthesis of the two key compounds 13 and 25 will be
described in the following. The synthesis of the remaining compounds
can be found in the Supporting Information.
(3-Amino-1H-indazol-5-yl)-[(2S)-2-(4-chlorophenyl)pyrrolidin-1-
yl]methanone (13). To a solution of 3-amino-1H-indazole-5-
carboxylic acid (50 mg, 0.28 mmol), 2-(4-chloro-phenyl)-pyrrolidine
hydrochloride (123 mg, 0.560 mmol) and 4-methylmorpholine (0.060
mL, 0.58 mmol) in N,N-dimethyl-formamide (2 mL) were added O-
(1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumtetraﬂuorobo-
rate (TBTU, 83 mg, 0.26 mmol) and 1-hydroxybenzotriazole hydrate
(HOBt, 9 mg, 0.07 mmol). The reaction mixture was stirred at RT for
15 h. Water was added to the mixture, and the resulting precipitate was
ﬁltered oﬀ and dried in vacuo. The crude product was puriﬁed by prep
HPLC (method A, acetonitrile/water) to yield 48 mg (50%) of (3-
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amino-1H-indazol-5-yl)-[2-(4-chlorophenyl)pyrrolidin-1-yl]-
methanone as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ
11.70−11.38 (m, 1H), 8.31−7.74 (m, 1H), 7.62−6.84 (m, 6H), 5.67−
5.27 (m, 2H), 5.16 (t, J = 7.0 Hz, 1H), 4.04−3.47 (m, 2H), 2.44−2.33
(m, 1H), 1.96−1.67 (m, 3H). LC−MS (method C, ESI, m/z) tR =
1.89 min, 341/343 (M + H)+.
Forty-three mg of the racemic mixture (0.13 mmol) of dissolved in
methanol (0.5 mL) were separated into the contained enantiomerically
pure materials by chiral HPLC in 25 μL/run portions according to
method C to yield in 8.9 mg (21%) of (3-amino-1H-indazol-5-yl)-
[(2S)-2-(4-chlorophenyl)pyrrolidin-1-yl]methanone as a brownish
solid and 8.6 mg (20%) of (3-amino-1H-indazol-5-yl)-[(2R)-2-(4-
chlorophenyl)pyrrolidin-1-yl]methanone as a brownish solid. HPLC/
MS (chiral, method C): Rt 3.47 min (compd 13), Rt 6.45 min (compd
ent-13). S-enantiomer: 1H NMR (500 MHz, DMSO-d6, mixture of
rotamers) δ 11.62−11.37 (bs, 1H), 8.34−7.97 (m, 1H), 7.63−6.88 (m,
6H), 5.49 (s, 2H), 5.16 (t, J = 7.1, 1H), 3.96−3.52 (m, 2H), 2.44−2.33
(m, 1H), 1.95−1.68 (m, 3H). 13C NMR (101 MHz, DMSO-d6, 3
signals missing) δ 169.4, 150.0, 143.4, 141.6, 130.8, 128.1, 127.4, 125.9,
120.9, 113.2, 108.8, 60.1, 51.0, 34.7, 25.1. LC−MS (method E, ESI, m/
z) tR = 1.89 min, 341/343 (M + H)
+. ESI-HRMS calcd for
C18H18
35ClN4O (M + H)
+, 341.1164; found, 341.1176.
[(2S)-2-(4-chlorophenyl)pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo-
[3,4-b]pyridin-5-yl)methanone (25). Into a 50 mL round-bottom
ﬂask, 3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid (0.500 g,
2.74 mmol), (S)-2-(4-chloro-phenyl)-pyrrolidine hydrochloride (0.720
g, 3.29 mmol), N-(3-(dimethylamino)propyl)-N′-ethylcarbodiimide
(1.06 g, 5.48 mmol), and 1-hydroxybenzotriazole hydrate (0.380 g,
2.74 mmol) were weighed in and dissolved in N,N-dimethylformamide
(10 mL). 4-Methylmorpholine (0.920 mL, 8.21 mmol) was added at
RT, and stirring was continued for 30 min at the same temperature.
The mixture was poured into a mixture of brine and water (1:1, 150
mL). The resulting beige precipitate was ﬁltered, washed with water,
and dried at 60 °C overnight to give 640 mg (69%) of [(2S)-2-(4-
chlorophenyl)pyrrolidin-1-yl]-(3-methyl-1H-pyrazolo[3,4-b]pyridin-5-
yl)methanone as beige solid. 1H NMR (400 MHz, DMSO-d6) δ
13.51−13.19 (m, 1H), 8.76−6.96 (m, 6H), 5.25−4.95 (m, 1H), 4.03−
3.51 (m, 2H), 2.62−2.28 (m, 4H), 2.00−1.68 (m, 3H). 13C NMR
(101 MHz, DMSO-d6, 1 signal missing) δ 167.3, 152.4, 148.1, 146.9,
143.0, 142.1, 130.9, 129.1, 128.1, 127.6, 124.9, 112.8, 60.4, 50.7, 34.8,
24.9, 12.2. LC−MS (method E, ESI, m/z) tR = 1.99 min, 341/343 (M
+ H)+. ESI-HRMS calcd for C18H18
35ClN4O (M + H)
+, 341.1164;
found, 341.1167.
All other experimental details (mouse, rat, and human Clint
determination; Caco-2 determination; in vivo mouse PK in-life
phase; in vivo rat and dog PK in-life phase; bioanalytics; prediction
of human clearance; in vitro cell-based reporter assays, 7dF3 luciferase
reporter assay; in vitro biochemical assays, CDK8 Lanthascreen
binding assay and reporter displacement assay for CDK19; human
tumor xenograft eﬃcacy study; pharmacokinetic analysis; tumor
xenograft processing; and Luminex analysis) are described in previous
publications.27,30 All animal experiments were conducted in
accordance with local and United Kingdom National Cancer Research
Institute guidelines.47
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